181 related articles for article (PubMed ID: 33314914)
1. Ultrasensitive Gastric Cancer Circulating Tumor Cellular
Fan L; Chong X; Zhao M; Jia F; Wang Z; Zhou Y; Lu X; Huang Q; Li P; Yang Y; Hu Z; Li Q; Zhang X; Shen L
Anal Chem; 2021 Jan; 93(2):665-670. PubMed ID: 33314914
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
Li J; Zhang Y; Hu D; Gong T; Xu R; Gao J
Aging (Albany NY); 2020 Jul; 12(14):14271-14284. PubMed ID: 32668412
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
4. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
5. Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling.
Xu X; Li Y; Zhang R; Chen X; Shen J; Yuan M; Chen Y; Chen M; Liu S; Wu J; Sun Q
J Ethnopharmacol; 2023 Jul; 311():116450. PubMed ID: 37023839
[TBL] [Abstract][Full Text] [Related]
6. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K; Ushiku T; Urabe M; Fukuyo M; Abe H; Ishikawa S; Seto Y; Aburatani H; Hamakubo T; Kaneda A; Fukayama M
Oncotarget; 2016 Sep; 7(39):64168-64181. PubMed ID: 27580354
[TBL] [Abstract][Full Text] [Related]
7. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
8. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
10. The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.
Abdallah EA; Braun AC; Flores BCTCP; Senda L; Urvanegia AC; Calsavara V; Fonseca de Jesus VH; Almeida MFA; Begnami MD; Coimbra FJF; da Costa WL; Nunes DN; Dias-Neto E; Chinen LTD
Oncologist; 2019 Sep; 24(9):e854-e863. PubMed ID: 30846515
[TBL] [Abstract][Full Text] [Related]
11. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.
Liu S; Zhang Z; Jiang L; Zhang M; Zhang C; Shen L
Cell Commun Signal; 2024 Jan; 22(1):27. PubMed ID: 38200591
[TBL] [Abstract][Full Text] [Related]
12. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
13. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
14. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
[TBL] [Abstract][Full Text] [Related]
15. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
16. miR-767-3p Inhibits Growth and Migration of Lung Adenocarcinoma Cells by Regulating CLDN18.
Wan YL; Dai HJ; Liu W; Ma HT
Oncol Res; 2018 May; 26(4):637-644. PubMed ID: 29169410
[TBL] [Abstract][Full Text] [Related]
17. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
Nakayama I; Shinozaki E; Sakata S; Yamamoto N; Fujisaki J; Muramatsu Y; Hirota T; Takeuchi K; Takahashi S; Yamaguchi K; Noda T
Cancer Sci; 2019 Apr; 110(4):1352-1363. PubMed ID: 30771244
[TBL] [Abstract][Full Text] [Related]
18. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
19. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
20. Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach.
Hagen SJ; Ang LH; Zheng Y; Karahan SN; Wu J; Wang YE; Caron TJ; Gad AP; Muthupalani S; Fox JG
Gastroenterology; 2018 Dec; 155(6):1852-1867. PubMed ID: 30195448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
